RhoVac's attending partnering meetings during January March 2020

RhoVac AB ('RhoVac') participates in international partnering meetings during January - March 2020.

CEO Anders Mansson will attend the following international partnering meetings during January - March 2020: 38th Annual J.P. Morgan Healthcare Conference, San Francisco, USA, 13-16 January 2020.

European Association of Urology (EAU), Amsterdam, 20-24 March 2020.

BIO-Europe Spring, Paris, 23-25 March 2020.

Contact:

Anders Mansson

Tel: [phone]

Email: [e-mail]

About RhoVac AB

RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has now passed the early stages of development. In 2018, the first clinical trial (phase I / II) was completed in prostate cancer, demonstrating that RV001 has good safety and is well tolerated, and that the drug provides the expected immune response that will exert its effect on the cancer cells. The strong immune response has also been shown to last over time. Therefore, RhoVac is immediately launching a major Phase IIb clinical trial that will include at least 175 prostate cancer patients. The study, which is expected to be completed in 2021, is designed to show, with statistical significance, the effect of RV001 in preventing disease progression in prostate cancer after surgery or radiation to the primary tumor. RhoVac is listed on Spotlight, Sweden, aMultilateral Trading Facility (MTF) since March 2016. The share is traded under the ticker RHOVAC.

(C) 2020 Electronic News Publishing, source ENP Newswire